PBYI Raises 2026 Nerlynx Outlook on Modest Growth; WAIT Thesis Intact

What happened

Puma Biotechnology raised its 2026 Nerlynx sales outlook after reporting 3.5% first-half 2026 growth, with Q3 revenue expected to reach $54-$56 million. This follows a period of stable U.S. product revenue around $195-$200 million annually, offset by volatile and declining royalty income from China. The raise is modest and mainly reflects continued U.S. demand, but it does not alter the single-product concentration or the structural gross-to-net pressure. The alisertib pipeline remains the key medium-term catalyst, with interim data still expected in H1 2026. Overall, the news supports the base case of stable Nerlynx revenue but does not resolve the royalty weakness or pipeline uncertainty.

Implication

The modestly higher 2026 Nerlynx outlook reinforces the base-case assumption of steady U.S. product revenue, but the royalty line remains depressed and the stock is already trading near fair value. Investors should not chase the shares above $6.65, as the limited upside to the bull case of $9.00 does not justify the downside risk to $4.50 if royalties stay weak or alisertib data disappoint. The WAIT rating remains appropriate, with an attractive entry point near $5.25 and a trim level above $8.00. Key events to monitor are the full FY 2026 guidance, any signs of royalty stabilization, and the H1 2026 alisertib interim readouts. Until those catalysts materialize, the risk-adjusted return is insufficient for new capital.

Thesis delta

The raised 2026 Nerlynx sales outlook modestly increases confidence in near-term product revenue stability, but it does not address the structural royalty decline or the lack of alisertib data. The WAIT rating and the $5.25 attractive entry / $8.00 trim levels remain unchanged.